Volker Neugebauer, MD, PhD, will use the grant from the National Institute of Neurological Disorders and Stroke to understand a process that causes hyperactivity in the amygdale and leads to persistent pain and anxiety.
Related Articles on Pain Management:
Convergence Pharmaceuticals Neuropatic Pain Drug Completes Phase I Trials
Trial for Boston Scientific’s Spinal Cord Stimulation Device Shows Promising Results
Oregon House Co-Speaker Visits Middle Fork Surgery Center for Pain Management Policy Discussion
